APRE vs. ACST, UBX, ENLV, LPCN, BIOR, NRXP, THTX, FBRX, ITRM, and ONCT
Should you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Acasti Pharma (ACST), Unity Biotechnology (UBX), Enlivex Therapeutics (ENLV), Lipocine (LPCN), Biora Therapeutics (BIOR), NRx Pharmaceuticals (NRXP), Theratechnologies (THTX), Forte Biosciences (FBRX), Iterum Therapeutics (ITRM), and Oncternal Therapeutics (ONCT). These companies are all part of the "pharmaceutical preparations" industry.
Aprea Therapeutics (NASDAQ:APRE) and Acasti Pharma (NASDAQ:ACST) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment, community ranking and analyst recommendations.
In the previous week, Aprea Therapeutics had 2 more articles in the media than Acasti Pharma. MarketBeat recorded 4 mentions for Aprea Therapeutics and 2 mentions for Acasti Pharma. Aprea Therapeutics' average media sentiment score of 0.46 beat Acasti Pharma's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media.
Aprea Therapeutics has higher revenue and earnings than Acasti Pharma. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Acasti Pharma, indicating that it is currently the more affordable of the two stocks.
34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 6.1% of Acasti Pharma shares are held by institutional investors. 20.9% of Aprea Therapeutics shares are held by insiders. Comparatively, 13.5% of Acasti Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Acasti Pharma received 266 more outperform votes than Aprea Therapeutics when rated by MarketBeat users. Likewise, 70.52% of users gave Acasti Pharma an outperform vote while only 51.72% of users gave Aprea Therapeutics an outperform vote.
Aprea Therapeutics currently has a consensus target price of $15.50, indicating a potential upside of 201.56%. Acasti Pharma has a consensus target price of $6.00, indicating a potential upside of 108.33%. Given Aprea Therapeutics' higher probable upside, analysts plainly believe Aprea Therapeutics is more favorable than Acasti Pharma.
Aprea Therapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Acasti Pharma has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.
Acasti Pharma's return on equity of -13.18% beat Aprea Therapeutics' return on equity.
Summary
Aprea Therapeutics beats Acasti Pharma on 9 of the 15 factors compared between the two stocks.
Get Aprea Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aprea Therapeutics Competitors List
Related Companies and Tools
